Banzel rufinamide oral suspension regulatory update

FDA accepted for filing an NDA from Eisai for Banzel rufinamide 40 mg/mL oral suspension for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 4 and u...